Archive for the ‘Announcements’ Category

Sanofi-Aventis Launches New Cancer Treatment

Tuesday, August 3rd, 2010

We congratulate our client, Sanofi-Aventis, on the launch of its new prostate cancer treatment, JEVTANA.  The FDA approved JEVTANA (cabazitaxel) on June 17, 2010 for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen.  Jevtana is administered intravenously.

Subsequently, Sanofi-Aventis launched JEVTANA in the United States on July 19, 2010.  Jevtana in combination with prednisone is the only FDA approved regimen to significantly improve overall survival in patients previously treated with docetaxel-based chemotherapy regimen."  Studies have shown that JEVTANA can increase survival by 30%.

We are proud to have played a role in helping Sanofi-Aventis bring this innovative and exciting treatment – and trademark – to market.

Bastille Day

Tuesday, July 13th, 2010

À nos clients et collègues français, nous vous souhaitons un joyeux Quatorze Juillet !

Program Note

Monday, April 27th, 2009

Please note that, for some reason, the blog does not render very well in Internet Explorer.  (Thank Microsoft, not us.)  However, it renders correctly in every other Window-based browser.  Therefore, we recommend viewing the blog in Firefox, Safari or Google Chrome if you are using Windows.  Any questions, let us know.

CTM Changes

Monday, February 25th, 2008

There are some recent changes to CTM and UK trademark law.

For CTM applications filed after 10 March 2008, CTM searches will be optional.  The CTM Register report will continue to be issued for all applications filed after 10 March 2008; however, separate individual searches will only be conducted and provided on request.  CTM applicants should note that the request for national searches must be made at the time the application is filed.  Applicants will not be able to request searches at a later time.  Moreover, the CTM Office will charge a separate fee for the searches (the amount has not yet been determined).

Finally, applicants should note that the option for national searches is “all or nothing”.  An applicant elects to receive searches from all 17 countries who currently provide search reports or none.  Applicants may not cherry-pick certain countries for which they would like to receive reports.

New rules at the UK Patent Office too:  In October 2007, the UK Intellectual Property Office stopped examining (and refusing) new applications on relative grounds (i.e., the existence of earlier registrations or applications).  Accordingly, prior U.K., CTM and IR registrations will no longer prevent new UK applications from maturing to registration.  While the IPO continues to conduct searches, it simply informs the applicant of any potentially conflicting mark.  The IPO automatically informs only the owners of prior U.K. and IR registrations of the new applications.  It does not automatically inform owners of earlier CTM registrations.  However, owners of CTM registrations may opt-in for notification.

*  Thanks to my friends at Graham Watt & Co. for this news.

Happy New Year!

Monday, December 31st, 2007

To all of our Clients, Colleagues and Readers:

newyears.jpg

We take this opportunity to wish you and your families a very happy and healthy new year!

Surprising.

Wednesday, July 11th, 2007

I just received a notification from the U.S. Trademark Trial & Appeal Board resetting some deadlines as a result of the death of Scott J. Fields on April 23, 2007.  Sad news indeed.

Pharma Consolidation

Monday, March 12th, 2007

Schering-Plough has announced that it will buy Akzo  Nobel N.V.’s drug unit N.V. Organon for $14.4 billion.

Akzo was expected to publish details of a plan to sell Organon shares today. Instead, this morning, the board signed the agreement with Schering-Plough. Talks began one and a half weeks ago, Chief Executive Hans Wijers told reporters on a conference call.

The transaction will boost Schering-Plough’s earnings per share by about 10 cents in the first year and close before the end of 2007, the U.S. drugmaker said.

FDA Issues Warnings on 3 Anemia Drugs

Saturday, March 10th, 2007

Federal health officials issued stern new warnings Friday for doctors to more carefully prescribe widely used anemia drugs that can increase the risk of death and other serious problems in patients with cancer and kidney disease.

The FDA’s press release can be viewed here.

At issue are drugs sold under the brand names Procrit, Epogen and Aranesp. These drugs are genetically engineered versions of a natural protein, erythropoietin, that increases the number of red blood cells.

INTA Update

Tuesday, March 7th, 2006

The International Trademark Association (“INTA”) has announced its redesigned website.

According to INTA, the “new format offers a modern and international appearance, an improved, easier navigation, and new user tools and features.”

I’ll be checking it out soon. In the meantime, visit the new site and let us know what you think.

See here also.

FIFA Beats Ferrero

Thursday, February 16th, 2006

Fifa has secured a landmark victory in a World Cup trademark row with confectionery company Ferrero.

Ferrero challenged EU rules banning companies unofficially associating themselves with next year’s World Cup in Germany.

However, the Office for Harmonization in the Internal Market ruled its attempts to register 11 marks, which included terms such as “World Cup Germany”, were unlawful.

The OHIM has also ruled against the commercial use of the internet domain name www.wm2006.com by a sports betting company, and confirmed that only Fifa’s commercial partners may use World Cup trademarks.